HHLR Advisors’s Sagimet Biosciences SGMT Stock Holding History

HHLR Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.79M	Hold	724,800	–	–	0.23%	18
2025 Q4	$4.29M	Hold	724,800	–	–	0.14%	17
2025 Q3	$4.97M	Hold	724,800	–	–	0.12%	22
2025 Q2	$5.52M	Hold	724,800	–	–	0.18%	23
2025 Q1	$2.36M	Hold	724,800	–	–	0.07%	32
2024 Q4	$3.26M	Hold	724,800	–	–	0.11%	25
2024 Q3	$2.01M	Hold	724,800	–	–	0.04%	34
2024 Q2	$2.48M	Hold	724,800	–	–	0.06%	51
2024 Q1	$3.93M	Sell	724,800 -724,743	-50%	-$5.2M	0.09%	38
2023 Q4	$7.86M	Hold	1,449,543	–	–	0.16%	31
2023 Q3	$12.8M	Buy	+1,449,543	New	+$19.3M	0.28%	32

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

HHLR Advisors's SGMT Position: Q1 2026 in Review

HHLR Advisors held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 724,800 shares worth $3.79M. The position accounts for 0.23% of the portfolio, ranked #18.

HHLR Advisors first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $12.8M in Q3 2023. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

HHLR Advisors held 724,800 shares of Sagimet Biosciences worth $3.79M as of Q1 2026.
HHLR Advisors left its Sagimet Biosciences share count unchanged in Q1 2026.
Sagimet Biosciences made up 0.23% of HHLR Advisors's portfolio in Q1 2026, its #18 holding.
HHLR Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
HHLR Advisors's Sagimet Biosciences position peaked at $12.8M in Q3 2023.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on HHLR Advisors's 13F filing for Q1 2026, filed 15 May 2026.